01—Abstract
Summary
Summary of the 8-K filed August 18, 2026. Cited figures are marked; the original filing is the authoritative source.
On August 18, 2026, AbbVie completed a $10.0 billiona underwritten senior notes offering spanning nine tranches, from 2028 floating-rate notes through 2066 fixed-rate notes.
The proceeds are earmarked to help fund the cash consideration for AbbVie's pending acquisition of Apogee Therapeutics, Inc., with any remainder going to general corporate purposes and related fees. The notes were issued under a shelf registration (S-3ASR dated February 14, 2025) and governed by the 2012 base indenture as supplemented by Supplemental Indenture No. 13. The filing is largely a debt-financing disclosure rather than an operating update.
The tranche structure is notable: $5.25 billionb (roughly 52%) is issued at maturities of 2028 to 2031, while $4.75 billion extends into 2033 through 2066, including $2.0 billion of long-dated 2056 and 2066 notes with coupons of 6.000% and 6.100%. The fixed coupons range from 4.500% to 6.100%, and the pricing curve reflects a meaningfully higher-rate environment at the long end. The 2028 floating-rate tranche and the 2028 fixed-rate notes both mature in August 2028, giving AbbVie a near-term maturity cluster to manage.
From an investor standpoint, the key contingent feature is the special mandatory redemption provision. If the Apogee acquisition is terminated or AbbVie informs the trustee it will not pursue it, AbbVie must redeem all notes other than the 2056 and 2066 notes at 101%c of principal plus accrued interest.
This limits downside for noteholders but also means the acquisition's completion is effectively tied to the debt structure. Investors should watch for closing of the Apogee deal and the resulting increase in AbbVie's total debt load, which the filing does not quantify beyond these offering amounts.
02—Key points
Key Highlights
- Completed a $10.0 billion, nine-tranche senior notes offering on August 18, 2026, ranging from a $500 million floating-rate note due 2028 to $500 million of 6.100% notes due 2066.
- Proceeds are earmarked to fund part of the cash consideration for the pending acquisition of Apogee Therapeutics, Inc., plus fees and expenses, with any remainder for general corporate purposes.
- Fixed coupons span 4.500% (2028 notes) to 6.100% (2066 notes), with the largest single tranches being $1.5 billion each in the 2031, 2036, and 2056 notes.
- Special mandatory redemption at 101% of principal is triggered if the Apogee acquisition is terminated or abandoned, applying to all notes except the 2056 and 2066 notes.
- Notes are unsecured, unsubordinated obligations ranking pari passu with all of AbbVie's existing and future unsecured, unsubordinated debt.
- Issued under a Form S-3ASR shelf registration (File No. 333-284980) and governed by the 2012 base indenture with U.S. Bank Trust Company as trustee, plus Supplemental Indenture No. 13.
- Make-whole optional redemption is available for all fixed-rate series, with par call dates ranging from February 2030 for the 2030 notes to March 2066 for the 2066 notes.
03—Questions
Frequently Asked Questions
How much debt did AbbVie raise in this offering?
AbbVie completed the offering of $10.0 billion aggregate principal amount of senior notes across nine series, including $500 million of floating-rate notes and eight fixed-rate series ranging from $500 million to $1.5 billion each.
What is the money being used for?
AbbVie expects to use the net proceeds to fund a portion of the aggregate cash consideration payable to Apogee Therapeutics shareholders in the pending acquisition, to pay related fees and expenses, and to fund general corporate purposes with any remainder.
What happens to the notes if the Apogee acquisition does not close?
If AbbVie publicly announces termination of the acquisition agreement or notifies the trustee it will not pursue the deal, it must redeem the floating-rate notes and the 2028, 2030, 2031, 2033, 2036, and 2038 notes at 101% of principal plus accrued interest. The 2056 and 2066 notes are not subject to this special redemption.
When do the notes mature?
The floating-rate notes and the 4.500% notes due 2028 mature on August 18, 2028. The 2030 notes mature on March 15, 2030, and the remaining series mature on September 15 of their respective years, through 2066 for the 6.100% notes.
Can AbbVie redeem the notes early?
Yes. The fixed-rate notes can be redeemed at a make-whole price at any time for the 2028 notes, and before their respective par call dates for the other series. After the par call dates, AbbVie may redeem at 100% of principal plus accrued interest.
04—Continue